|
Celldex Therapeutics inc (NASDAQ: CLDX) |
|
Celldex Therapeutics inc
CLDX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Celldex Therapeutics Inc 's sales fell
by -71.56 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 88
In Vitro & In Vivo Diagnostic Substances industry recorded
growth of revenues by 3.39 %
Celldex Therapeutics Inc net loss increased from $-43 millions, to $-47 millions in IV. Quarter 2024,
• More on CLDX's Growth
|
|
Celldex Therapeutics Inc realized a net loss in trailing twelve months.
Celldex Therapeutics Inc realized cash reduction of $ -0.1 per share in trailing twelve-month period. In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 179.63.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 6.97.
• More on CLDX's Valuation
|
|
|
|
|
Celldex Therapeutics Inc realized net loss in trailing twelve months.
Celldex Therapeutics Inc realized cash outflow of $ -0.1per share in trailing twelve-month period. In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 179.63.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 6.97.
Celldex Therapeutics Inc Price to Book Ratio is at 1.69 lower than Industry Avg. of 553.62. and higher than S&P 500 Avg. of 0.01
• More on CLDX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com